Clinical Trials Sponsored by Elixir Pharmaceuticals

Total 19724 results

Elixir Pharmaceuticals

Completed

Drug-Drug Interaction Study of Mitiglinide and Gemfibrozil

Type 2 Diabetes Mellitus
Elixir Pharmaceuticals

Completed

Mitiglinide in Combination With Metformin vs. Metformin Alone in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States, Puerto Rico
Elixir Medical Corporation

Active, not recruiting

A Clinical Trial to Assess the Elixir Medical LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter (PINNACLE-I)

Coronary Artery Disease

Netherlands, Belgium
Elixir Medical Corporation

Recruiting

DynamX Bioadaptor Global Post-Market Registry: Clinical Trial of the Elixir Medical DynamX Novolimus Eluting Coronary Bioadaptor System (Bio-RESTORE)

Coronary Artery Disease

Saudi Arabia
Elixir Medical Corporation

Completed

Elixir Medical Clinical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - The DESolve Nx Trial

Coronary Artery Disease

New Zealand, Belgium, Germany, Poland, Denmark, Brazil
Elixir Medical Corporation

Completed

Evaluation of a Thin Strut Metallic Stent: the Elixir DynamX Clinical Study

Coronary Artery Disease

Belgium, Italy
Elixir Medical Corporation

Completed

EXCELLA Post-Approval Study

Coronary Artery Disease

Jordan, Germany, Spain
Elixir Medical Corporation

Completed

Elixir Medical Clinical Evaluation of the Novolimus-Eluting Coronary Stent System: A Randomized Study "EXCELLA II STUDY"

Coronary Artery Disease

Switzerland, New Zealand, Belgium, Poland, Australia, Brazil, Germany, Netherlands
University of Zurich
Lokman Hekim Üniversitesi; Elixir Pharmaceuticals

Completed

Delayed-release Bedtime Caffeine and Sleep Inertia Symptoms Immediately Upon Awakening

Caffeine | Placebo | Sleep Inertia

Switzerland
Elixir Medical Corporation

Terminated

DESyne X2 Post Market Follow-up Study (DESyne X2 PMCF)

Coronary Artery Disease

China
Elixir Medical Corporation

Completed

Elixir Medical Clinical Evaluation of the DESolve Myolimus Eluting Bioresorbable Coronary Stent System - DESolve I Trial

Coronary Artery Disease

New Zealand, Belgium
Elixir Medical Corporation

Active, not recruiting

The Elixir Bioadaptor vs. The Onyx Stent in De Novo Native Coronary Arteries (BIOADAPTOR RCT)

Coronary Artery Disease | Coronary Disease | Coronary Stenosis | Coronary Artery Stenosis

New Zealand, Belgium, Germany, Japan
Elixir Medical Corporation

Active, not recruiting

The DESyne BDS Plus RCT: A Randomized Clinical Trial to Assess the Elixir DESyne BDS Plus Drug Eluting Coronary Stent System for the Treatment of de Novo Native Coronary Artery Lesions

Coronary Artery Disease

New Zealand, Belgium, Netherlands, Czechia, Brazil
Elixir Medical Corporation

Completed

DynamX Bioadaptor Hong Kong Registry

Coronary Artery Disease

China
Elixir Medical Corporation

Completed

Elixir Medical Evaluation of the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System - Cx Registry

Coronary Artery Disease

Belgium, Brazil
Elixir Medical Corporation

Completed

DynamX Sirolimus Study Sirolimus Eluting Coronary Bioadaptor System

Coronary Artery Disease

New Zealand
Elixir Medical Corporation

Completed

DESolve Post-Approval Study

Coronary Artery Disease

Jordan, Germany, Italy
Elixir Medical Corporation
Uppsala University

Active, not recruiting

Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT)

Coronary Artery Disease | Ischemic Heart Disease

Sweden
Elixir Medical Corporation
Istituto Clinico Humanitas

Active, not recruiting

DYNAMX Bioadaptor ImplanTation for the trEatment of Complex Coronary Lesions (DYNAMITE)

Coronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery Disease

Italy
Elicio Therapeutics

Active, not recruiting

A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors (AMPLIFY-201)

Colorectal Cancer | Ovarian Cancer | Cholangiocarcinoma | Bile Duct Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma | Minimal Residual Disease | Gallbladder Carcinoma | KRAS G12D | KRAS G12R | NRAS G12D | NRAS G12R

United States
Elixir Medical Corporation
Massachusetts General Hospital; Syntactx; Genae

Completed

The DESappear Study: Drug Eluting Scaffold (DESappear)

Peripheral Vascular Disease

New Zealand, Austria, Germany, Belgium
Elixir Medical Corporation
European Cardiovascular Research Center

Terminated

DESolve® X-Pand Global Post Market Registry (X-Pand)

Coronary Artery Stenosis

Germany, Netherlands
Elicio Therapeutics

Recruiting

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors (AMPLIFY-7P)

Colorectal Cancer | Pancreatic Ductal Adenocarcinoma | KRAS G12D | KRAS G12R | NRAS G12D | NRAS G12R | KRAS G12V | KRAS G12C | KRAS G12A | KRAS G12S | KRAS G13D | NRAS G12V | NRAS G12C | NRAS G12S

United States
Elixiron Immunotherapeutics Inc.

Recruiting

First in Human Study of EI-001 Monoclonal Antibody in Healthy Volunteers

Healthy

Australia
Lihir Medical Centre

Completed

PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs )

Trauma | Lymphatic Filariasis | Yaws

Papua New Guinea
Lihir Medical Centre

Withdrawn

Prednisone Plus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly (LiHMS)

Malaria | Anaemia | Hyper-reactive Malarial Splenomegaly

Papua New Guinea
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Elvir SAS
BioFortis

Completed

Study on Effects of a Dairy Product Based on Polyphenols and Enriched With Vitamins B6, B9 and B12 on Some Cardiovascular Factor of Risk

Cardiovascular Risk Factors

France
Elixiron Immunotherapeutics Inc.
Parexel

Completed

A Study to Evaluate the Safety, Tolerability and Amount of EI-1071 in Blood in Healthy Volunteers

Healthy Volunteers

United States
M.D. Anderson Cancer Center
Eligix

Terminated

CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation

Multiple Myeloma | Chronic Lymphocytic Leukemia | Chronic Myelogenous Leukemia | Non Hodgkin's Lymphoma | Hodgkin's Disease

United States
Ohio State University
Velimir Matkovic

Withdrawn

Effects of Whole Body Vibration in Elderly Patients Requiring Rehabilitation: A Pilot Study

Neuromuscular Deficits | Musculoskeletal Deficits

United States
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, United Kingdom
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

RSV Infection

United States
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Hepatitis C

Belgium, United States, Puerto Rico, Netherlands
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

To Assess the Patients' Ability to Self-Administer Fasinumab (FACT DEVICE)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Alexza Pharmaceuticals, Inc.
Pharmaceutical Research Associates

Unknown

Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

Agitation,Psychomotor

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects

RSV Infection

United States
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

HIV Infections | Hepatitis C

France, Spain, United States, Germany
Tibotec Pharmaceuticals, Ireland
Tibotec Pharmaceutical Limited

Completed

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents (DIONE)

HIV-1 Infection

France, United States, Spain, Ukraine, United Kingdom, Ireland
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants

Renal Impairment
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Hepatic Impairment
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip (FACT OA2)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment

Chronic HBV Infection

Hong Kong, Taiwan
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee (FACT CLBP 1)

Osteoarthritis | Chronic Low Back Pain

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

RSV Infection

United States
Melior Pharmaceuticals
Bukwang Pharmaceutical, Co., Ltd.

Completed

Adult Subjects With Uncontrolled Type 2 Diabetes

Type 2 Diabetes

United States
Tibotec Pharmaceuticals, Ireland
Tibotec Pharmaceutical Limited

Completed

A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected Children

Human Immunodeficiency Virus 1

South Africa, Argentina, Brazil, India, Kenya
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study to Examine the Effects of Telaprevir on the Pharmacokinetics of Cyclosporine and Tacrolimus in Healthy Adults

Hepatitis C

United States

Clinical Trials Sponsored by Elixir Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations